Compare Mesoblast Limited (MESO) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Southern Copper Corp — how do they compare? Mesoblast Limited trades at $14.13 (market cap $1.75B), while Southern Copper Corp trades at $205.87 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 95.9× Mesoblast Limited's market cap, and Southern Copper Corp pays a 2.21% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Southern Copper Corp for 61 Days on average.
| MESO | SCCO | |
|---|---|---|
Market Cap | $1.75B | $167.74B |
Volume | 239,027 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $20.96 | $219.70 |
52-Week Low | $13.19 | $120.02 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | $1.83B | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Southern Copper (SCCO) trades at $200.57, down 1.81% on the day, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and net income margins expanding to 35.87%. Recent earnings have consistently beaten expectations, and the company maintains robust profitability metrics including 50.07% ROE. A stock split and dividend payment are scheduled for August 2026.
SCCO presents a mixed investment case with strong operational performance offset by premium valuations. The stock trades above analyst consensus target of $167.67, suggesting limited near-term upside. Key risks include copper price volatility and competitive pressures, while growth catalysts include Mexican project pipeline development. Analyst sentiment remains divided with only 10.34% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
